Several innovative medications are reshaping blood sugar management, with Retatrutide, Cagrillintide, Tirzepatide, and Semaglutide being highlighted leading choices. Retatrutide, a double GIP and GLP-1 site agonist, demonstrates significant weight loss coupled with better glycemic levels. Cagrillintide, one GLP-1 stimulant, is currently in clinical